1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Review Pathways

FDA Neurology Clinical Team Leader Departure May Be Mountain Disguised As Molehill

 
• By Ramsey Baghdadi

Attention to the departure of neurology reviewer Ron Farkas from FDA has focused on what it means for Sarepta’s eteplirsen application, but there are larger regulatory environment issues that deserve more scrutiny.

FDA entrance sign 2016

Like most controversies today, it started with a tweet.

“Seems like Ron Farkas is no longer at the @US_FDA cc $SRPT” Jenn McNary, one of the most active Duchenne Muscular Dystrophy patient advocates and a mother of a son with DMD, wrote on Sept

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards